China Resources Boya: nine-month revenue down 42.54%, profit down 81.82%
China Resources Boya Bio-pharmaceutical: 9M revenue down 42.54%, attributable profit down 81.82%, focus shifts to blood products, per TradingView.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, China Resources Boya Bio-pharmaceutical's revenue for the first nine months fell 42.54% year on year, to ¥846.9 million. Net profit attributable to shareholders dropped 81.82%, to ¥62.3 million.
The decline is linked to procurement policy, insurance-related cost controls, VAT changes and stronger competition. At the same time, the company sold Nanjing Xinbai and received a new plasma collection license, a sign that it is concentrating on blood products.
why it matters
For the market this is a story about one Chinese pharma company, but the sharp profit drop and strategic shift matter to investors who follow plasma-derived therapy makers. The numbers show how pricing and cost pressure can weigh on an entire segment.
tags
instruments
sources
- China Resources Boya Bio-pharmaceutical Group: 9M revenue fell 42.54% as earnings slumped and focus shifted to blood products — TradingView, 29 October 2026 at 08:53 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗